Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe

European Cancer and Cognition Consortium (ECCC), Charlotte Sleurs, Ali Amidi, Lisa M Wu, David Kiesl, Philipp Zimmer, Marie Lange, Anne Rogiers, Benedicte Giffard, Giulia Binarelli, Cindy Borghgraef, Sabine Deprez, Mylène Duivon, Michiel De Ruiter, Sanne Schagen, Djihane Ahmed-Lecheheb, Hélène Castel, Cecilie R Buskbjerg, Mélanie Dos Santos, Florence JolyJoy Perrier*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)
50 Downloads (Pure)


Cancer-related cognitive impairment (CRCI) has increasingly been identified over the last two decades in non-CNS system cancer patients. Across Europe, researchers have contributed to this effort by developing preclinical models, exploring underlying mechanisms and assessing cognitive and quality of life changes. The ultimate goal is to develop interventions to treat patients experiencing CRCI. To do so, new challenges need to be addressed requiring the implementation of multidisciplinary research groups. In this consensus paper, we summarize the state of the art in the field of CRCI combined with the future challenges and action plans in Europe. These challenges include data sharing/pooling, standardization of assessments as well as assessing additional biomarkers and neuroimaging investigations, notably through translational studies. We conclude this position paper with specific actions for Europe based on shared scientific expert opinion and stakeholders involved in the Innovative Partnership for Action Against Cancer, with a particular focus on cognitive intervention programs.

Original languageEnglish
Article number103859
JournalCritical Reviews in Oncology/Hematology
Publication statusPublished - 2022


  • Humans
  • Quality of Life
  • Cognitive Dysfunction/diagnosis
  • Neoplasms/therapy
  • Biomarkers
  • Europe


Dive into the research topics of 'Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe'. Together they form a unique fingerprint.

Cite this